A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.

ABSTRACT: BACKGROUND:Ulcerative colitis (UC) is a chronic autoimmune inflammation of the colon. The condition significantly decreases quality of life and generates a substantial economic burden for healthcare payers, patients and the society in which they live. Some patients require chronic pharmacotherapy, and access to novel biologic drugs might be crucial for long-term remission. The analyses of cost-effectiveness for biologic drugs are necessary to assess their efficiency and provide the best available drugs to patients. OBJECTIVE:Our aim was to collect and assess the quality of economic analyses carried out for biologic agents used in the treatment of UC, as well as to summarize evidence on the drivers of cost-effectiveness and evaluate the transferability and generalizability of conclusions. M

SUBMITTER: Stawowczyk E 

PROVIDER: S-EPMC5840213 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature